Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2006;114:1829-1837
Published online before print October 9, 2006, doi: 10.1161/CIRCULATIONAHA.106.649426
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
114/17/1829    most recent
CIRCULATIONAHA.106.649426v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jankowska, E. A.
Right arrow Articles by Ponikowski, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jankowska, E. A.
Right arrow Articles by Ponikowski, P.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Heart Failure
*Seniors' Health
Hazardous Substances DB
*TESTOSTERONE
Related Collections
Right arrow Congestive

(Circulation. 2006;114:1829-1837.)
© 2006 American Heart Association, Inc.


Heart Failure

Anabolic Deficiency in Men With Chronic Heart Failure

Prevalence and Detrimental Impact on Survival

Ewa A. Jankowska, MD, PhD; Bartosz Biel, MD; Jacek Majda, PhD; Alicja Szklarska, PhD; Monika Lopuszanska, MSc; Marek Medras, MD, PhD; Stefan D. Anker, MD, PhD; Waldemar Banasiak, MD, PhD; Philip A. Poole-Wilson, MD, FRCP; Piotr Ponikowski, MD, PhD

From Cardiology Department, Military Hospital (E.A.J., B.B., J.M., W.B., P.P.), Wroclaw, Poland; Institute of Anthropology, Polish Academy of Sciences (E.A.J., A.S., M.L.), Wroclaw, Poland; Cardiac Medicine, Royal Brompton Hospital (E.A.J., S.D.A., P.A.P.-W.), National Heart and Lung Institute, Imperial College London, London, United Kingdom; Endocrinology and Diabetology Department, Wroclaw Medical University (M.M.), Wroclaw, Poland; and Division of Applied Cachexia Research, Department of Cardiology, Charité (S.D.A.), Berlin, Germany.

Correspondence to Ewa A. Jankowska, MD, PhD, Cardiology Department, Military Hospital, ul. Weigla 5, 50-981 Wroclaw, Poland. E-mail Ewa.Jankowska{at}antro.pan.wroc.pl

Received January 31, 2005; de novo received July 3, 2006; accepted August 11, 2006.

Background— The age-related decline of circulating anabolic hormones in men is associated with increased morbidity and mortality. We studied the prevalence and prognostic consequences of deficiencies in circulating total testosterone (TT) and free testosterone, dehydroepiandrosterone sulfate (DHEAS), and insulin-like growth factor-1 (IGF-1) in men with chronic heart failure (CHF).

Methods and Results— Serum levels of TT, DHEAS, and IGF-1 were measured with immunoassays in 208 men with CHF (median age 63 years; median left ventricular ejection fraction 33%; New York Heart Association class I/II/III/IV, 19/102/70/17) and in 366 healthy men. Serum levels of free testosterone were estimated (eFT) from levels of TT and sex hormone binding globulin. Deficiencies in DHEAS, TT, eFT, and IGF-1, defined as serum levels at or below the 10th percentile of healthy peers, were seen across all age categories in men with CHF. DHEAS, TT, and eFT were inversely related to New York Heart Association class irrespective of cause (all P<0.01). DHEAS correlated positively with left ventricular ejection fraction and inversely with N-terminal pro-brain natriuretic peptide (both P<0.01). Circulating TT, eFT, DHEAS, and IGF-1 levels were prognostic markers in multivariable models when adjusted for established prognostic factors (all P<0.05). Men with CHF and normal levels of all anabolic hormones had the best 3-year survival rate (83%, 95% CI 67% to 98%) compared with those with deficiencies in 1 (74% survival rate, 95% CI 65% to 84%), 2 (55% survival rate, 95% CI 45% to 66%), or all 3 (27% survival rate, 95% CI 5% to 49%) anabolic endocrine axes (P<0.0001).

Conclusions— In male CHF patients, anabolic hormone depletion is common, and a deficiency of each anabolic hormone is an independent marker of poor prognosis. Deficiency of >1 anabolic hormone identifies groups with a higher mortality.


 

CLINICAL PERSPECTIVE




This article has been cited by other articles:


Home page
Arch Intern MedHome page
M. Maggio, F. Lauretani, G. P. Ceda, S. Bandinelli, S. M. Ling, E. J. Metter, A. Artoni, L. Carassale, A. Cazzato, G. Ceresini, et al.
Relationship Between Low Levels of Anabolic Hormones and 6-Year Mortality in Older Men: The Aging in the Chianti Area (InCHIANTI) Study
Arch Intern Med, November 12, 2007; 167(20): 2249 - 2254.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
D. A. Pascual-Figal, P. L. Tornel, and M. Valdes
Letter by Pascual-Figal et al Regarding Article, "Anabolic Deficiency in Men With Chronic Heart Failure: Prevalence and Detrimental Impact on Survival"
Circulation, May 29, 2007; 115(21): e548 - e548.
[Full Text] [PDF]


Home page
CirculationHome page
E. A. Jankowska, B. Biel, J. Majda, W. Banasiak, P. Ponikowski, M. Lopuszanska, A. Szklarska, S. D. Anker, P. A. Poole-Wilson, and M. Medras
Response to Letter Regarding Article, "Anabolic Deficiency in Men With Chronic Heart Failure: Prevalence and Detrimental Impact on Survival"
Circulation, May 29, 2007; 115(21): e549 - e549.
[Full Text] [PDF]